TY - JOUR T1 - Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 1629 LP - 1634 DO - 10.21873/anticanres.15638 VL - 42 IS - 3 AU - IKKO TOMISAKI AU - MIRII HARADA AU - AKINORI MINATO AU - YUJIRO NAGATA AU - RIEKO KIMURO AU - KATSUYOSHI HIGASHIJIMA AU - KENICHI HARADA AU - NAOHIRO FUJIMOTO Y1 - 2022/03/01 UR - http://ar.iiarjournals.org/content/42/3/1629.abstract N2 - Background/Aim: This study aimed to clarify the impact of proton pump inhibitors (PPIs) on oncological outcomes in patients who received pembrolizumab for advanced urothelial carcinoma (UC). Patients and Methods: Forty advanced UC patients treated with pembrolizumab were retrospectively reviewed and divided into two groups (PPI: 15 patients; without PPI: 25 patients). Tumor response and survival were compared between these groups. The factors associated with survival were also investigated. Results: The objective response rate was significantly lower in the group with PPIs compared with the group without PPIs. Both progression-free survival (PFS) and overall survival (OS) were significantly shorter in the group with PPIs than in the group without PPIs. The use of PPIs was a significant predictor of poor PFS and OS in multivariate analysis. Conclusion: The use of PPIs was negatively associated with tumor response and survival in patients with advanced UC treated with pembrolizumab. ER -